Tomoko Iwata

Biberach An Der Riss, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial.

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial.

Journal: JACC. Heart failure

Published: June 15, 2024

Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: February 22, 2024

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Journal: Journal of cachexia, sarcopenia and muscle

Published: September 05, 2023

Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.

Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: May 18, 2023

Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.

Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.

Journal: European journal of heart failure

Published: January 10, 2023

Health status across major subgroups of patients with heart failure and preserved ejection fraction.

Health status across major subgroups of patients with heart failure and preserved ejection fraction.

Journal: European journal of heart failure

Published: October 21, 2022

Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis.

Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis.

Journal: JACC. Heart failure

Published: October 06, 2022

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.

Journal: Circulation

Published: September 13, 2022

Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.

Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.

Journal: Journal of the American College of Cardiology

Published: August 24, 2022

Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.

Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.

Journal: JACC. Heart failure

Published: May 06, 2022

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.

Journal: European journal of heart failure

Published: April 14, 2022

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.

Journal: Journal of the American College of Cardiology

Published: March 15, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026